Skip to content

US · HIND · BIOTECHNOLOGY

Vyome Holdings, Inc. (HIND) intrinsic value and stock valuation

$1.20as of 2026-11-21 · Mkt cap 15.02M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Vyome Holdings, Inc. DCF and intrinsic value

InvestorsCraft values HIND with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from HIND’s statements →

Vyome Holdings, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Cambridge, MA 02138 vyometx.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$320K-51% 5y CAGRd
20112025
Net income
-$-10.26M
20112025
Free cash flow
-$-3.75M
20112025
Total equity
$3.76M-23.6% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$320K$8.01M$8.68M$11.2M$13.6M
Operating income-$-2.75M-$-7.73M-$-14.64M-$-27.08M-$-57.88M
Net income-$-10.26M-$-7.13M-$-11.39M-$-46.21M-$-63.15M
EPSd-$-4.75M-$-356.5M———
Operating cash flow-$-3.75M-$-4.43M-$-16.96M-$-21.9M-$-15.38M
Capital expenditure$0.00$0.00-$-40K-$-130K-$-350K
Free cash flow-$-3.75M-$-4.43M-$-17M-$-22.03M-$-15.73M
Total assets$6.5M$4.79M$10.7M$11.3M$52.5M
Total debt$30K$970K$260K$170K$280K
Net debt-$-4.95M$270K-$-4.3M-$-3.78M-$-22.49M
Total equity$3.76M-$-250K$6.66M$3.66M$44.3M
Cash and short-term investments$4.98M$690K$4.56M$3.96M$22.8M
Income statement
20252024202320222021
Revenue$320K$8.01M$8.68M$11.2M$13.6M
Cost of revenue$110K$2.95M$3.13M$4.44M$5.25M
Gross profit$210K$5.06M$5.55M$6.8M$8.35M
Research and development expenses$590K$1.8M$2.31M$2.54M$2.37M
Selling, general and administrative expenses$2.37M$9.92M$17.9M$31.3M$33.2M
Other expenses$0.00$1.06M$0.00$0.00$30.7M
Operating expenses$2.95M$12.8M$20.2M$33.9M$66.2M
Cost and expenses$3.07M$15.7M$23.3M$38.3M$71.5M
Interest income$0.00$10K$30K$0.00$0.00
Interest expense$150K$0.00$0.00$110K$830K
Depreciation and amortization$10K$20K$150K$2.15M$1.97M
Ebitda-$-10.32M-$-6.65M-$-11.18M-$-44.33M-$-60.62M
Operating income-$-2.75M-$-7.73M-$-14.64M-$-27.08M-$-57.88M
Total other income/expenses, net-$-7.73M$640K$3.3M-$-19.52M-$-5.54M
Income before tax-$-10.48M-$-7.09M-$-11.34M-$-46.59M-$-63.42M
Income tax expense$0.00$40K$50K-$-380K-$-270K
Net income-$-10.26M-$-7.13M-$-11.39M-$-46.21M-$-63.15M
Weighted average shares outstanding$2.16M$20K$0.00$0.00$0.00
Weighted average diluted shares outstanding$2.16M$20K$0.00$0.00$0.00
Balance sheet
20252024202320222021
Cash and short-term investments$4.98M$690K$4.56M$3.96M$22.8M
Net receivables$100K$1.03M$1.66M$2.18M$2.81M
Inventory$0.00$2.46M$3.74M$3.61M$3M
Total current assets$5.44M$4.59M$10.3M$9.91M$29.9M
Property, plant and equipment, net$80K$150K$310K$870K$1.72M
Goodwill and intangible assets$310K$0.00$0.00$260K$20.8M
Long-term investments$600K$0.00$0.00$0.00$0.00
Total non-current assets$1.06M$200K$430K$1.35M$22.6M
Total assets$6.5M$4.79M$10.7M$11.3M$52.5M
Accounts payable$650K$2.21M$1.69M$1.93M$3.47M
Short-term debt$30K$930K$110K$170K$280K
Deferred revenue$0.00$720K$0.00$0.00$550K
Total current liabilities$2.74M$4.99M$3.78M$7.48M$7.53M
Long-term debt$0.00$40K$150K$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$60K$290K$120K$670K
Capital lease obligations$0.00$160K$150K$0.00$280K
Total liabilities$2.74M$5.05M$4.06M$7.6M$8.2M
Common stock$10K$0.00$20K$0.00$0.00
Retained earnings-$-87.56M-$-642.7M-$-635.57M-$-624.19M-$-577.97M
Accumulated other comprehensive income (loss)-$-80K-$-100K-$-90K-$-90K-$-90K
Total equity$3.76M-$-250K$6.66M$3.66M$44.3M
Total investments$600K$0.00$0.00$0.00$0.00
Total debt$30K$970K$260K$170K$280K
Net debt-$-4.95M$270K-$-4.3M-$-3.78M-$-22.49M
Cash flow statement
20252024202320222021
Net income-$-10.48M-$-7.13M-$-11.39M-$-46.21M-$-35.46M
Depreciation and amortization$10K$20K$150K$2.15M$1.97M
Stock-based compensation$6.58M$180K$770K$2.09M$12.2M
Change in working capital$40K$2.29M-$-4.13M$710K-$-2.74M
Accounts receivable$0.00$560K$120K$680K-$-280K
Inventory$0.00$920K-$-470K-$-1.19M-$-370K
Accounts payable$170K$820K-$-3.46M$450K-$-1.48M
Net cash provided by operating activities-$-3.75M-$-4.43M-$-16.96M-$-21.9M-$-15.38M
Investments in property, plant and equipment$0.00$0.00-$-40K-$-130K-$-350K
Acquisitions, net$0.00$0.00$0.00$40K$2.21M
Net cash used for investing activities$0.00$0.00-$-10K-$-90K$1.85M
Common stock issued$7.86M$20K$17.6M$640K$42.8M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$8.65M$680K$17.6M$3.13M$33.3M
Net change in cash$4.88M-$-3.77M$600K-$-18.86M$19.8M
Cash at end of period$4.98M$790K$4.56M$3.96M$22.8M
Operating cash flow-$-3.75M-$-4.43M-$-16.96M-$-21.9M-$-15.38M
Capital expenditure$0.00$0.00-$-40K-$-130K-$-350K
Free cash flow-$-3.75M-$-4.43M-$-17M-$-22.03M-$-15.73M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Vyome Holdings, Inc.

        Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.

        CEO
        Venkateswarlu Nelabhotla
        Employees
        18
        Beta
        1.49

        Explore

        Frequently asked questions

        What is the intrinsic value of Vyome Holdings, Inc. (HIND)?

        InvestorsCraft does not currently publish an intrinsic value for HIND. How the IC value is calculated.

        Is HIND undervalued?

        InvestorsCraft does not publish an undervaluation signal for HIND at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.